Welcome to our dedicated page for Apellis Pharmace news (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmace stock.
Apellis Pharmaceuticals, Inc. reports news on its commercial-stage biopharmaceutical business centered on complement science and C3-targeting medicines. Recurring updates cover SYFOVRE, a pegcetacoplan injection for geographic atrophy secondary to age-related macular degeneration, and EMPAVELI, pegcetacoplan for rare diseases including paroxysmal nocturnal hemoglobinuria and rare kidney indications.
Company news also includes product revenue updates, ophthalmology and nephrology data presentations, pipeline references tied to complement biology, board and governance changes, investor conference participation, collaboration matters, and corporate-status developments involving strategic transactions and related shareholder communications.
Apellis Pharmaceuticals (Nasdaq: APLS) announced a $300 million private placement of 3.500% convertible senior notes due 2026, with an aggregate purchase price of $328.9 million. The deal closing is expected on May 12, 2020. The notes will be unsecured senior obligations, maturing on September 15, 2026, with an initial conversion rate of 25.3405 shares per $1,000 principal amount. Net proceeds of approximately $323 million will fund clinical development of pegcetacoplan and support commercialization efforts.
Summary not available.